Technical Analysis for RETA - Reata Pharmaceuticals, Inc. - Class A

Grade Last Price % Change Price Change
grade C 182.83 -14.43% -30.84
RETA closed down 14.43 percent on Tuesday, November 12, 2019, on 4.44 times normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Down
See historical RETA trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
New 52 Week High Strength 0.00%
Earnings Movers Other 0.00%
Multiple of Ten Bearish Other 0.00%
Outside Day Range Expansion 0.00%
Stochastic Reached Overbought Strength -14.43%
Wide Bands Range Expansion -14.43%
Overbought Stochastic Strength -14.43%

Older signals for RETA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.
Medicine Diseases Inflammation Health Care Pulmonary Arterial Hypertension Pulmonary Hypertension Myopathy Friedreich's Ataxia Interstitial Lung Disease
Is RETA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 217.47
52 Week Low 47.5
Average Volume 543,944
200-Day Moving Average 97.4183
50-Day Moving Average 131.2984
20-Day Moving Average 195.429
10-Day Moving Average 205.029
Average True Range 12.0802
ADX 57.41
+DI 25.2641
-DI 22.7023
Chandelier Exit (Long, 3 ATRs ) 181.2294
Chandelier Exit (Short, 3 ATRs ) 131.73059999999999
Upper Bollinger Band 223.4475
Lower Bollinger Band 167.4105
Percent B (%b) 0.28
BandWidth 28.673841
MACD Line 21.8747
MACD Signal Line 25.8533
MACD Histogram -3.9786
Fundamentals Value
Market Cap 4.77 Billion
Num Shares 26.1 Million
EPS -1.06
Price-to-Earnings (P/E) Ratio -172.48
Price-to-Sales 15.55
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 235.84
Resistance 3 (R3) 241.50 229.48 227.01
Resistance 2 (R2) 229.48 215.98 226.66 224.06
Resistance 1 (R1) 206.16 207.64 200.15 200.50 221.11
Pivot Point 194.14 194.14 191.14 191.32 194.14
Support 1 (S1) 170.82 180.64 164.81 165.16 144.55
Support 2 (S2) 158.80 172.30 155.98 141.60
Support 3 (S3) 135.48 158.80 138.66
Support 4 (S4) 129.82